MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol

Oncogene

Volumn 32, Issue 4, 2013, Pages 431-443

  Yu, Y H ^a,b   Chen, H A ^c,d   Chen, P S ^e,f   Cheng, Y J ^g   Hsu, W H ^a   Chang, Y W ^h   Chen, Y H ^a   Jan, Y ⁱ   Hsiao, M ⁱ   Chang, T Y ^g   Liu, Y H ^a   Jeng, Y M ^f   Wu, C H ^c,d   Huang, M T ^c,d   Su, Y H ^c,d   Hung, M C ^a,g   Chien, M H ^c,j   Chen, C Y ^a   Kuo, M L ^e,f   Su, J L ^a,b,g,k  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

^h NATIONAL YANG MING UNIVERSITY   (Taiwan)

ⁱ GENOMICS RESEARCH CENTER   (Taiwan)

^j TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^k ASIA UNIVERSITY   (Taiwan)

more..

Author keywords

FOXC2; metastasis; miR 520h; resveratrol

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 520H; PROTEIN KINASE B; RESVERATROL; TRANSCRIPTION FACTOR FOXC2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; MICRORNAS; NF-KAPPA B; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT; STILBENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873056468     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.74     Document Type: Article

References (54)

1. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989; 8: 98-101.
2. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
3. Kim JB, Islam S, Kim YJ, Prudoff RS, Sass KM, Wheelock MJ et al. N-Cadherin extracellular repeat 4 mediates epithelial to mesenchymal transition and increased motility. J Cell Biol 2000; 151: 1193-1206.
4. Ngan CY, Yamamoto H, Seshimo I, Tsujino T, Man-i M, Ikeda JI et al. Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer. Br J Cancer 2007; 96: 986-992.
5. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003; 5: 217-222.
6. Zavadil J, Cermak L, Soto-Nieves N, Bottinger EP. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J 2004; 23: 1155-1165.
7. Timmerman LA, Grego-Bessa J, Raya A, Bertran E, Perez-Pomares JM, Diez J et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev 2004; 18: 99-115.
8. Barrallo-Gimeno A, Nieto MA. The Snail genes as inducers of cell movement and survival: Implications in development and cancer. Development 2005; 14: 3151-3161.
9. Alves CC, Carneiro F, Hoefler H, Becker KF. Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front Biosci 2009; 14: 3035-3050.
10. Browne G, Sayan AE, Tulchinsky E. ZEB proteins link cell motility with cell cycle control and cell survival in cancer. Cell Cycle 2010; 9: 886-991.
11. Hamamori Y, Wu HY, Sartorelli V, Kedes L. The basic domain of myogenic basic helix-loop-helix (bHLH) proteins is the novel target for direct inhibition by another bHLH protein, Twist. Mol Cell Biol 1997; 17: 6563-6573.
12. Hartwell KA, Muir B, Reinhardt F, Carpenter AE, Sgroi DC, Weinberg RA. The Spemann organizer gene, Goosecoid, promotes tumor metastasis. Proc Natl Acad Sci USA 2006; 103: 18969-18974.
13. Mani SA, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA 2007; 104: 10069-10074.
14. Hader C, Marlier A, Cantley L. Mesenchymal-epithelial transition in epithelial response to injury: The role of Foxc2. Oncogene 2010; 29: 1031-1040.
15. Nishida N, Mimori K, Yokobori T, Sudo T, Tanaka F, Shibata K et al. FOXC2 is a Novel Prognostic Factor in Human Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2011; 2: 535-542.
16. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
17. Saiko P, Szakmary A, Jaeger W, Szekeres T. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res 2008; 658: 68-94.
18. Holmes-McNary M, Baldwin Jr AS. Chemopreventive properties of transresveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res 2000; 60: 3477-3483.
19. Choi HK, Yang JW, Kang KW. Bifunctional effect of resveratrol on the expression of ErbB2 in human breast cancer cell. Cancer Let 2006; 242: 198-206.
20. Li Q, Li J, Ren J. UCF-101 mitigates streptozotocin-induced cardiomyocyte dysfunction: role of AMPK. Am J Physiol Endocrinol Metab 2009; 4: 965-973.
21. Woo JH, Lim JH, Kim YH, Suh SI, Min DS, Chang JS et al. Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene 2004; 23: 1845-1853.
22. Aziz MH, Nihal M, Fu VX, Jarrard DF, Ahmad N. Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 30-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther 2006; 5: 1335-1341.
23. Stewart JR, Ward NE, Ioannides CG, O'Brian CA. Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, argininerich protein substrate by a novel mechanism. Biochemistry 1999; 38: 13244-13251.
24. Stewart JR, Christman KL, O'Brian CA. Effects of resveratrol on the autophosphorylation of phorbol ester-responsive protein kinases: Inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation. Biochem Pharmacol 2000; 60: 1355-1359.
25. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel A, Kel O et al. Databases on transcriptional regulation: TRANSFAC, TRRD, and COMPEL. Nucleic Acids Res 1998; 26: 364-370.
26. Aggarwal BB. Nuclear factor-jB:The enemy within. Cancer Cell 2004; 6: 203-208.
27. Gronning LM, Cederberg A, Miura N, Enerback S, Tasken K. Insulin and TNF alpha induce expression of the forkhead transcription factor gene Foxc2 in 3T3-L1 adipocytes via PI3K and ERK 1/2-dependent pathways. Mol Endocrinol 2002; 16: 873-883.
28. Hayashi H, Kume T. Foxc transcription factors directly regulate Dll4 and Hey2 expression by interacting with the VEGF-Notch signaling pathways in endothelial cells. PLoS One 2008; 3: E2401.
29. Sun HZ, Yang TW, Zang WJ, Wu SF. Dehydroepiandrosterone-induced proliferation of prostatic epithelial cell is mediated by NFKB via PI3K/AKT signaling pathway. Eur J Endocrinol/Eur Fed Endocr Soc 2010; 204: 311-318.
30. Liao Y HM. A new role of protein phosphatase 2a in adenoviral E1A proteinmediated sensitization to anticancer drug-induced apoptosis in human breast cancer cells. Cancer Res 2004; 64: 5938-5942.
31. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-789.
32. Su JL, Chen PB, Chen YH, Chen SC, Chang YW, Jan YH et al. Downregulation of microRNA miR-520h by E1A contributes to anticancer activity. Cancer Res 2010; 70: 5096-5108.
33. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys 2009; 486: 95-102.
34. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res 2004; 24: 2783-2840.
35. Kume T, Jiang H, Topczewska JM, Hogan BL. The murine winged helix transcription factors, Foxc1 and Foxc2, are both required for cardiovascular development and somitogenesis. Genes Dev 2001; 15: 2470-2482.
36. Sano H, Leboeuf JP, Novitskiy SV, Seo S, Zaja-Milatovic S, Dikov MM et al. The Foxc2 transcription factor regulates tumor angiogenesis. Biochem Biophys Res Commun 2010; 392: 201-206.
37. Topczewska JM, Topczewski J, Shostak A, Kume T, Solnica-Krezel L, Hogan BL. The winged helix transcription factor Foxc1a is essential for somitogenesis in zebrafish. Genes Dev 2001; 15: 2483-2493.
38. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-4751.
39. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 30 kinase/AKT pathways. Oncogene 2005; 24: 7443-7454.
40. Lu Y, Wahl LM. Production of matrix metalloproteinase-9 by activated human monocytes involves a phosphatidylinositol-3 kinase/Akt/IKKalpha/NF-kappaB pathway. J Leukoc Biol 2005; 78: 259-265.
41. Agarwal A, Das K, Lerner N, Sathe S, Cicek M, Casey G et al. The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin. Oncogene 2005; 24: 1021-1031.
42. Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van Roy F et al. Activation of NFkappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 2007; 26: 7445-7456.
43. Millward TA, Zolnierowicz S, Hemmings BA. Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci 1999; 24: 186-191.
44. Perrotti D, Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev 2008; 27: 159-168.
45. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005; 8: 355-368.
46. Feschenko MS, Stevenson E, Nairn AC, Sweadner KJ. A novel cAMP-stimulated pathway in protein phosphatase 2A activation. J Pharmacol Exp Ther 2002; 302: 111-118.
47. Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol 2003; 138: 1303-1312.
48. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
49. Korpal M, Kang Y. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 2008; 5: 115-119.
50. Tili E, Michaille JJ, Adair B, Alder H, Limagne E, Taccioli C et al. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis 2010; 31: 1561-1566.
51. Tili E, Michaille JJ, Alder H, Volinia S, Delmas D, Latruffe N et al. Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFbeta signaling pathway in SW480 cells. Biochem Pharmacol 2010; 80: 2057-2065.
52. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008; 10: 202-210.
53. Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, Johansson G et al. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res 2010; 70: 7830-7840.
54. Kuhn H, Liebers U, Gessner C, Schumacher A, Witt C, Schauer J et al. Adenorivusmediated E2F-1 gene transfer in nonsmall-cell lung cancer induces cell growth arrest and apoptosis. Eur Respir J 2002; 20: 703-709.